Core Viewpoint - The company has received approval from the National Medical Products Administration of China for its self-developed chemical Class 1 new drug SYH2070 injection, a double-stranded small interfering RNA (siRNA) drug, to conduct clinical trials in China [1] Group 1: Product Details - SYH2070 is designed for liver-targeted delivery of siRNA through the conjugation of N-acetylgalactosamine (GalNAc) and aims to target angiopoietin-like protein 3 (ANGPTL3) to effectively lower ANGPTL3 levels [1] - The product utilizes optimized sequences and chemical modifications to achieve a more prolonged gene silencing effect, positioning it as a long-acting siRNA drug suitable for treating hypertriglyceridemia or mixed hyperlipidemia [1] - It has the potential to effectively reduce the risk of elevated residual cholesterol levels [1] Group 2: Clinical Development Value - Preclinical studies indicate that SYH2070 demonstrates superior drug activity and efficacy duration compared to similar siRNA products, showcasing differentiated advantages such as sustained drug effects, good safety profile, and high patient compliance [1] - The product holds significant clinical development value due to its promising characteristics [1]
石药集团(01093)：SYH2070注射液(双链小干扰RNA药物)在中国获临床试验批准